Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 179

1.

A small molecule TrkB ligand reduces motor impairment and neuropathology in R6/2 and BACHD mouse models of Huntington's disease.

Simmons DA, Belichenko NP, Yang T, Condon C, Monbureau M, Shamloo M, Jing D, Massa SM, Longo FM.

J Neurosci. 2013 Nov 27;33(48):18712-27. doi: 10.1523/JNEUROSCI.1310-13.2013. Erratum in: J Neurosci. 2014 Jan 29;34(5):2012.

2.

Imbalance of p75(NTR)/TrkB protein expression in Huntington's disease: implication for neuroprotective therapies.

Brito V, Puigdellívol M, Giralt A, del Toro D, Alberch J, Ginés S.

Cell Death Dis. 2013 Apr 18;4:e595. doi: 10.1038/cddis.2013.116.

3.

Reduced expression of the TrkB receptor in Huntington's disease mouse models and in human brain.

Ginés S, Bosch M, Marco S, Gavaldà N, Díaz-Hernández M, Lucas JJ, Canals JM, Alberch J.

Eur J Neurosci. 2006 Feb;23(3):649-58.

PMID:
16487146
4.

Fingolimod (FTY720) enhances hippocampal synaptic plasticity and memory in Huntington's disease by preventing p75NTR up-regulation and astrocyte-mediated inflammation.

Miguez A, García-Díaz Barriga G, Brito V, Straccia M, Giralt A, Ginés S, Canals JM, Alberch J.

Hum Mol Genet. 2015 Sep 1;24(17):4958-70. doi: 10.1093/hmg/ddv218. Epub 2015 Jun 10.

PMID:
26063761
5.

Selective reduction of striatal mature BDNF without induction of proBDNF in the zQ175 mouse model of Huntington's disease.

Ma Q, Yang J, Li T, Milner TA, Hempstead BL.

Neurobiol Dis. 2015 Oct;82:466-77. doi: 10.1016/j.nbd.2015.08.008. Epub 2015 Aug 15.

6.

The mGluR5 positive allosteric modulator, CDPPB, ameliorates pathology and phenotypic signs of a mouse model of Huntington's disease.

Doria JG, de Souza JM, Andrade JN, Rodrigues HA, Guimaraes IM, Carvalho TG, Guatimosim C, Dobransky T, Ribeiro FM.

Neurobiol Dis. 2015 Jan;73:163-73. doi: 10.1016/j.nbd.2014.08.021. Epub 2014 Aug 24.

PMID:
25160573
7.

The antidepressant sertraline improves the phenotype, promotes neurogenesis and increases BDNF levels in the R6/2 Huntington's disease mouse model.

Peng Q, Masuda N, Jiang M, Li Q, Zhao M, Ross CA, Duan W.

Exp Neurol. 2008 Mar;210(1):154-63. Epub 2007 Nov 9.

8.

Brain-derived neurotrophic factor over-expression in the forebrain ameliorates Huntington's disease phenotypes in mice.

Gharami K, Xie Y, An JJ, Tonegawa S, Xu B.

J Neurochem. 2008 Apr;105(2):369-79. Epub 2007 Dec 12.

9.

Small-molecule TrkB receptor agonists improve motor function and extend survival in a mouse model of Huntington's disease.

Jiang M, Peng Q, Liu X, Jin J, Hou Z, Zhang J, Mori S, Ross CA, Ye K, Duan W.

Hum Mol Genet. 2013 Jun 15;22(12):2462-70. doi: 10.1093/hmg/ddt098. Epub 2013 Feb 27.

10.

Environmental enrichment rescues protein deficits in a mouse model of Huntington's disease, indicating a possible disease mechanism.

Spires TL, Grote HE, Varshney NK, Cordery PM, van Dellen A, Blakemore C, Hannan AJ.

J Neurosci. 2004 Mar 3;24(9):2270-6.

11.

A small molecule p75NTR ligand normalizes signalling and reduces Huntington's disease phenotypes in R6/2 and BACHD mice.

Simmons DA, Belichenko NP, Ford EC, Semaan S, Monbureau M, Aiyaswamy S, Holman CM, Condon C, Shamloo M, Massa SM, Longo FM.

Hum Mol Genet. 2016 Nov 15;25(22):4920-4938. doi: 10.1093/hmg/ddw316.

12.

The p75 neurotrophin receptor augments survival signaling in the striatum of pre-symptomatic Q175(WT/HD) mice.

Wehner AB, Milen AM, Albin RL, Pierchala BA.

Neuroscience. 2016 Jun 2;324:297-306. doi: 10.1016/j.neuroscience.2016.02.069. Epub 2016 Mar 3.

13.

Impaired TrkB Signaling Underlies Reduced BDNF-Mediated Trophic Support of Striatal Neurons in the R6/2 Mouse Model of Huntington's Disease.

Nguyen KQ, Rymar VV, Sadikot AF.

Front Cell Neurosci. 2016 Mar 9;10:37. doi: 10.3389/fncel.2016.00037. eCollection 2016.

14.

Dendritic spine instability leads to progressive neocortical spine loss in a mouse model of Huntington's disease.

Murmu RP, Li W, Holtmaat A, Li JY.

J Neurosci. 2013 Aug 7;33(32):12997-3009. doi: 10.1523/JNEUROSCI.5284-12.2013.

15.

Dendritic spine pathology and deficits in experience-dependent dendritic plasticity in R6/1 Huntington's disease transgenic mice.

Spires TL, Grote HE, Garry S, Cordery PM, Van Dellen A, Blakemore C, Hannan AJ.

Eur J Neurosci. 2004 May;19(10):2799-807.

PMID:
15147313
16.

Mutant Huntingtin alters retrograde transport of TrkB receptors in striatal dendrites.

Liot G, Zala D, Pla P, Mottet G, Piel M, Saudou F.

J Neurosci. 2013 Apr 10;33(15):6298-309. doi: 10.1523/JNEUROSCI.2033-12.2013.

17.

Overexpression of BDNF and Full-Length TrkB Receptor Ameliorate Striatal Neural Survival in Huntington's Disease.

Silva A, Naia L, Dominguez A, Ribeiro M, Rodrigues J, Vieira OV, Lessmann V, Rego AC.

Neurodegener Dis. 2015;15(4):207-18. doi: 10.1159/000375447. Epub 2015 Apr 21. Erratum in: Neurodegener Dis. 2015;15(4):258.

PMID:
25896770
18.

Treatment with a herbal formula B401 enhances neuroprotection and angiogenesis in the R6/2 mouse model of Huntington's disease.

Wang SE, Lin CL, Hsu CH, Sheu SJ, Chien CT, Wu CH.

Drug Des Devel Ther. 2015 Feb 16;9:887-900. doi: 10.2147/DDDT.S78015. eCollection 2015.

19.

Synaptic scaling up in medium spiny neurons of aged BACHD mice: A slow-progression model of Huntington's disease.

Rocher AB, Gubellini P, Merienne N, Boussicault L, Petit F, Gipchtein P, Jan C, Hantraye P, Brouillet E, Bonvento G.

Neurobiol Dis. 2016 Feb;86:131-9. doi: 10.1016/j.nbd.2015.10.016. Epub 2015 Nov 25.

PMID:
26626081
20.

Phosphodiesterase type IV inhibition prevents sequestration of CREB binding protein, protects striatal parvalbumin interneurons and rescues motor deficits in the R6/2 mouse model of Huntington's disease.

Giampà C, Middei S, Patassini S, Borreca A, Marullo F, Laurenti D, Bernardi G, Ammassari-Teule M, Fusco FR.

Eur J Neurosci. 2009 Mar;29(5):902-10. doi: 10.1111/j.1460-9568.2009.06649.x.

PMID:
19291221

Supplemental Content

Support Center